布地奈德联合肺表面活性物质对早产儿支气管肺发育不良的临床疗效  

Clinical effects of budesonide combined with pulmonary surfactant on bronchopulmonary dysplasia in preterm infants

作　　者：朱曦怡[1] 温志红[1] 李福兵 谢钰雁 韦秀珍[1] ZHU Xiyi;WEN Zhihong;LI Fubing;XIE Yuyan;WEI Xiuzhen(Department of Pediatrics,the People's Hospital of Guangxi Zhuang Autonomous Regin,Nanning 530021,China)

机构地区：[1]广西壮族自治区人民医院儿科,南宁530021

出　　处：《中国中西医结合儿科学》2021年第4期277-280,共4页Chinese Pediatrics of Integrated Traditional and Western Medicine

基　　金：广西壮族自治区卫生和计划生育委员会自筹经费科研课题(Z20180701)。

摘　　要：目的探讨布地奈德联合肺表面活性物质(PS)预防早产儿支气管肺发育不良(BPD)的发生。方法选取2018年1月至2020年6月本院收治的呼吸窘迫综合征早产儿80例为研究对象,随机分为对照组和观察组各40例。对照组给予PS治疗,观察组给予布地奈德联合PS治疗。分析两组患儿治疗期间主要并发症、BPD发生率及严重程度、持续气道正压(CPAP)应用失败率、PS再次使用率等指标。结果观察组生后2、3、4 d氧合指数高于对照组,差异有统计学意义(P<0.05)。观察组患儿BPD发生率、PS再次使用率均低于对照组,差异有统计学意义(P<0.05)。两组CPAP治疗失败率和中-重度BPD发生率比较差异无统计学意义(P>0.05)。观察组呼吸支持使用时间、住院费用低于对照组,差异有统计学意义(P<0.05);两组总住院时间比较差异无统计学意义(P>0.05)。两组治疗期间早产儿视网膜病、晚发型败血症、坏死性小肠结肠炎、动脉导管未闭发生率比较差异无统计学意义(P>0.05)。结论布地奈德联合PS治疗早产儿Ⅱ~Ⅲ级呼吸窘迫综合征,能改善早产儿肺功能,减少早产儿BPD的发生。Objective To study the effects of budesonide combined with pulmonary surfactant(PS)in preventing bronchopulmonary dysplasia(BPD)in preterm infants.Methods A total of 80 preterm infants with respiratory distress syndrome(RDS)treated in our hospital from January 2018 to June 2020 were randomly divided into control group and observation group,40 in each group.The control group were treated by PS only,and the observation group were treated by budesonide combined with PS.The main complications,incidence of BPD and severity,the failure rate of continuous positive airway pressure(CPAP)application and the rate of using PS again were compared between the two groups.Results Oxygenation index was higher on day 2,3 and 4 in observation group than in control group(P<0.05).The incidence of BPD and the rate of using PS again were lower in the observation group than in control group(P<0.05).The failure rate of CPAP and the incidence of moderate-severe BPD were lower in the observation group,but there were no statistical difference(P>0.05).The respiratory support time and hospitalization costs were lower in observation group than in the control group(P<0.05).There was no statistical difference in the total hospitalization time between the two groups(P>0.05).There was no significant difference in the incidence of retinopathy of prematurity,late-onset sepsis,necrotizing enterocolitis and patent ductus arteriosus between the two groups(P>0.05).Conclusion Budesonide combined with PS can be used to treat premature infants with grade Ⅱ-Ⅲ RDS,which can improve the lung function of premature infants and decrease the incidence of BPD.

关 键 词：支气管肺发育不良 布地奈德 肺表面活性物质 

分 类 号：R725.6[医药卫生—儿科]